New York, May 29, 2026, 15:02 (EDT)
- Pharvaris shares traded flat on the Nasdaq in the afternoon after the company detailed fresh clinical data presentations for June.
- Deucrictibant, the company’s oral drug candidate for hereditary angioedema, a rare swelling disorder, is the main focus.
- Investors are watching for a planned U.S. filing in the first half of 2026, with Phase 3 prevention data due out in the third quarter.
Pharvaris N.V. inched up Friday after the Dutch drugmaker said its main angioedema drug will have clinical data presented at a top allergy and immunology event next month.
Shares traded at $30.00 in afternoon Nasdaq action, up around 0.5%, after swinging from $29.58 to $30.34. The SPDR S&P Biotech ETF was up by about 0.5%, but the iShares Nasdaq Biotechnology ETF dipped 0.2%. Pharvaris tracked pretty close to other small-cap biotechs.
The move was small. The timing stood out.
Pharvaris said it got one abstract in for an oral presentation and seven more for flash-talk or poster slots at the European Academy of Allergy and Clinical Immunology congress in Istanbul, set for June 12-15. The oral will cover end-of-progression data from RAPIDe-3, the Phase 3 study of deucrictibant immediate-release capsules for treating hereditary angioedema attacks on demand.
Pharvaris is out to get deucrictibant approved both as a treatment for HAE attacks and as a preventive. Hereditary angioedema, or HAE, can bring on swelling attacks that hit the abdomen, limbs, or airway.
Deucrictibant is a bradykinin B2 receptor antagonist, or a drug meant to block swelling signals in the body. Pharvaris is working on an immediate-release form for treating attacks and an extended-release tablet for prevention.
Pharvaris N.V. says its New Drug Application for the immediate-release capsule is still set for the first half of 2026, and it’s on track to get topline results from CHAPTER-3, a Phase 3 trial of the extended-release tablet in HAE prevention, in the third quarter.
Chief Executive Berndt Modig said earlier this month the company is still “focused on execution across our late-stage programs,” mentioning both CHAPTER-3 and work on commercial prep for deucrictibant IR if approved. Modig also said they’re keeping a “disciplined approach to capital allocation” after raising new funds. Pharvaris N.V.
Pharvaris wrapped up a $132.3 million underwritten offering on May 11. The deal moved 4,455,863 ordinary shares, with underwriters taking their full option. All shares came from Pharvaris itself. The company said it plans to use the cash for late-stage research, building U.S. sales and marketing, commercialization, working capital and general corporate purposes.
KalVista Pharmaceuticals is already out front. The company got U.S. approval last year for EKTERLY, or sebetralstat, billed as the first and only oral on-demand HAE attack treatment for patients 12 and up.
Deal interest is picking up in the category. Italy’s Chiesi said in April it plans to acquire KalVista for about $1.9 billion, Reuters reported, pointing to EKTERLY as a major asset for its rare-disease strategy.
Pharvaris isn’t just targeting an acute-attack pill. The company wants to have both on-demand and preventive oral drugs, while BioCryst’s ORLADEYO is already cleared as an oral prophylactic for HAE attacks.
On the downside, more congress data might not move the debate unless it boosts confidence in efficacy, safety, and real-world use. The bigger catalysts are still with regulators and CHAPTER-3. Pharvaris has flagged risks including FDA interactions, trial timelines and outcomes, if results can be repeated in later studies, competition, and the cost to build commercial operations.
